ClinicalTrials.gg
RecruitingNCT06548958Updated Mar 13, 2025

A Single-Arm, Prospective Study of TBI+BUMEL as Conditioning for SCT2 in Patients With Malignant Hematologic Diseases

An interventional study of Second Stem Cell Transplantation (SCT2) in Malignant Hematological Diseases, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 14 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by The First Affiliated Hospital of Soochow University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
14 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Hematologic Diseases with a site in China — 19 open to participants now, 25 under way, 8 of them phase 3. Hematologic Diseases · China.

Planned enrollment
33rd of 52
40 · median 62
Started
2024
with 3 others
No phase
12 of 65
5 open now
Primary completion
2027-03
later than 12 of 24 live
Registered
47th of 65
by date
Lead sponsor
5 of 65
The First Affiliated Hospital of Soochow University

Among the 65 studies in Hematologic Diseases with a site in China, this one is the 33rd largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 with no phase, reaches primary completion later than 12 of the 24 other live ones, and was the 47th registered.

Hematologic Diseases

610 studies on the registry are indexed under Hematologic Diseases; 109 are open to participants now.

Browse Hematologic Diseases studies →

Open to participants now

19 of the 65 studies in Hematologic Diseases with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 73 Hematologic Diseases studies recruiting now, 46 (63%) set no upper age limit and 23 (32%) stop at 75 or younger; 28 take children under 18; 4 take healthy volunteers.

This study: 14 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Hematologic Diseases with a site in China, or all of them as a file.
02

Study summary

Each year, over 20,000 patients in China undergo hematopoietic stem cell transplantation (HSCT). Unfortunately, the prognosis in patients with disease relapse or graft failure is often inferior. A second allogeneic hematopoietic stem cell transplantation (SCT2) has emerged as a vital salvage therapy option. Despite varying prognoses, most patients undergoing SCT2 have a five-year overall survival (OS) rate of less than 30%. The primary challenges of SCT2 include treatment strategy, immune regulation, complication management, and transplantation technique improvements. By optimizing these key aspects, SCT2 can effectively address issues that arose after the first transplant, reduce complications, and provide more effective treatment for patients.

Clinical practice indicates that SCT2 is crucial in treating various hematologic diseases. For patients who failed the first transplant (SCT1), SCT2 can more effectively treat the primary disease, provide timely hematopoietic engraftment, extend survival time, and improve the quality of life. Additionally, the successful application of SCT2 provides clinicians with more treatment options and hope. Currently, the modified BU/CY conditioning regimen, which consists of busulfan (BU) and cyclophosphamide (CY), is commonly used in SCT1 in China. However, for patients who relapse after SCT1, these drugs may become ineffective, and the physical condition often worsens, with a higher likelihood of infections and organ dysfunction. Therefore, finding new conditioning regimens is crucial.

Studies have shown that a melphalan (MEL)-based conditioning regimen may have better outcomes for patients with acute myeloid leukemia (AML) compared to a Cy-based regimen. The Conditioning regimen that includes total body irradiation (TBI) has also been considered effective for patients with acute leukemia. Thus, low-dose TBI combined with a BU + MEL regimen could be a promising conditioning regimen for SCT2. In the investigators' preliminary studies, three patients who underwent SCT2 with this regimen successfully achieved engraftment and were discharged.

Based on this, the investigators plan to conduct a clinical study to observe the effects of the TBI+BUMEL regimen combined with SCT2 on the engraftment rate, disease relapse rate, GVHD incidence, and survival rate in patients with malignant hematologic diseases who relapsed after SCT1.

Read the detailed description

The primary challenges of SCT2 include:

  1. treatment strategy: eliminating residual tumor cells and addressing graft failure;
  2. immune regulation: adjusting the immune system to ensure successful engraftment of new stem cells;
  3. complication management: due to the poor physical condition of patients after the first transplant (SCT1), the risk of complications after SCT2 is high. This necessitates special attention to the prevention and management of post-transplant complications;
  4. transplantation technique improvements: more rigorous donor screening, HLA typing, monitoring, and supportive treatment during the transplant procedure.
03

Conditions studied

  • Malignant Hematological Diseases

Browse trials for

Keywords

  • Second Allogeneic Hematopoietic Stem Cell Transplantation
  • Malignant Hematological Diseases
  • Total Body Irradiation
  • Melphalan
  • Conditioning Regimen
04

Who can participate

Ages eligible
14 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender is not limited, patients between 14 to 70 years old (including critical value);
  2. Malignant hematological diseases (acute/chronic myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, malignant lymphoma, etc.) diagnosed by bone marrow aspiration or according to the WHO diagnostic criteria, after the first hematopoietic stem cell transplantation, due to various reasons (including but not limited to disease relapse or graft failure) have indications for a second hematopoietic stem cell transplantation;
  3. The indexes of cardiac function, liver and kidney function were within the following limits: (1) (ALT) and aspartate aminotransferase (AST) ≤ 3× (ULN); (2)Total ≤ 3×ULN; (3) Serum creatinine ≤ 2×ULN or ≥ 40mL/min; (4) (LVEF) as measured by echocardiography or multi-gated acquisition (MUGA) scan is within the normal range (> 50%);
  4. Having a suitable allogeneic hematopoietic stem cell donor;
  5. Expected survival ≥3 months;
  6. (KPS) score ≥60%, Eastern Tumor Cooperative group () status ≤ 2;
  7. Patient fully understood the nature of the study, and voluntarily participates and signs .

Exclusion criteria

Exclusion Criteria:

  1. Patients had serious adverse reactions to drugs such as allergies;
  2. Patients with a history of immunodeficiency, or other acquired or congenital diseases, immunodeficiency diseases, and a history of organ transplantation;
  3. Patients with hypertension, ventricular arrhythmia requiring clinical intervention, acute coronary syndrome, congestive heart failure, stroke, or other grade III or higher cardiovascular events within 6 months;
  4. Received Class II or higher surgery within 4 weeks prior to enrollment;
  5. Patients with active viral infections;
  6. Pregnant or lactating patients;
  7. The patient is currently participating in another clinical studies;
  8. Patients deemed unsuitable for inclusion by other investigators.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    40 patients with malignant hematological diseases who undergo SCT2

    patients undergo SCT2 using TBI + BUMEL as a conditioning regimen

    Procedure: Second Stem Cell Transplantation (SCT2)

Interventions

  • ProcedureSecond Stem Cell Transplantation (SCT2)

    1. Conditioning Regimen Day -7: Semustine (Me-CCNU) 250mg/m², orally; Day -6: Total Body Irradiation (TBI) 4Gy; Day -5 to Day -4: Busulfan (Bu) 3.2mg/kg/day, administered in four divided doses, IV infusion; Day -3 to Day -2: Melphalan (Mel) 50mg/m²/day, IV infusion; 2. Donor Stem Cell Infusion (Second Hematopoietic Stem Cell Transplantation) Day 0: Intravenous infusion of donor hematopoietic stem cells (MNC ≥ 8×10⁸/kg, CD34+ cells ≥ 4×10⁶/kg).

06

What researchers measure

Primary outcomes

  1. The cumulative incidence of neutrophil engraftment and platelet engraftment

    Neutrophil and platelet engraftment is defined as the first occurrence of 3 consecutive days with an absolute neutrophil count of at least 0.5×109/L and a platelet count of over 20×109/L for 7 consecutive days without transfusion support.

    Time frame: on day 28±7 following SCT2

  2. The time to reconstitution of hematopoiesis

    Recovery of hemopoietic function after treatment

    Time frame: on day 28±7 following SCT2

  3. The cumulative incidence of transplant-related mortality (TRM)

    Transplant-related mortality was defined as mortality due to any cause other than disease progression within 100 days of transplantation.

    Time frame: within 100 days following SCT2

Secondary outcomes

  1. The cumulative incidence and grade of graft-versus-host disease (GVHD)

    Graft-versus-host disease (GvHD) is a medical complication following the receipt of transplanted tissue from a genetically different person.

    Time frame: within 1 year following SCT2

  2. The cumulative incidence of relapse

    We defined relapse as any clinical evidence of progression or recurrence of original diseases.

    Time frame: within 1 year following SCT2

  3. Overall survival rate

    We estimated OS from the time of transplant until the date of death of any cause or last follow-up for patients still alive.

    Time frame: within 1 year following SCT2

  4. The cumulative incidence of adverse events

    Following extraction of the tumor, a blood vessel burst causing increased blood loss during the procedure, an adverse event the surgeon did not expect.

    Time frame: within 1 year following SCT2

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Mar 2027, 32 months after the start.

Of 51 non-industry interventional studies with no phase under Hematologic Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 49. This study's planned 32 months is below that.

Counting every sponsor, half of 54 studies reached it within 37 months; a quarter within 22 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 12, 2024
StartActual
Jul 10, 2024
Primary completionEst.
Mar 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06548958
Responsible party
Sponsor
First posted
Aug 12, 2024
Start date
Jul 10, 2024
Primary completion
Mar 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Mar 13, 2025

Study contacts

Xiaojin Wu, Prof.
Contact
wuxiaojin@suda.edu.cn
13057493105
Depei Wu, Prof.
Contact
wudepei@suda.edu.cn
13951102021
Depei Wu, Prof.
principal investigator · The First Affiliated Hospital of Soochow University
Xiaojin Wu, Prof.
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion